Company Overview

The company’s commercial operations are centred around its Next-Generation Sequencing (NGS)-based DNA break-mapping platform, INDUCE-seq.

Following the close of its $15M Series A funding round in 2023, Broken String has been focused on delivering a scalable ‘Platform as a Service’ offering and extension of the technology’s capabilities beyond gene-editing.